Belgium Considers Regulated Psychedelic Therapy Access for Depression

Belgium May Permit Psychedelic Therapy Beyond Trials

Belgium is actively considering a regulatory framework that would allow psychedelic-assisted therapy for treatment-resistant depression (TRD) outside the confines of formal clinical trials. This policy shift, reported on October 16, 2026, would make Belgium one of the first European Union (EU) jurisdictions to enable broader, regulated patient access to psychedelic treatments such as psilocybin or MDMA for severe depression unresponsive to conventional therapies. The Belgian Federal Agency for Medicines and Health Products (FAMHP) is reportedly leading the policy review, in consultation with psychiatric associations and patient advocacy groups.

Mechanisms and Context: From Trials to Real-World Access

The mechanism under discussion involves establishing a controlled access program, where certified clinicians could prescribe psychedelic-assisted therapy to eligible patients with documented TRD. This approach would require strict eligibility criteria, mandatory clinician training, and ongoing patient monitoring. Belgium's consideration follows recent advances in Phase II and III clinical trials for psychedelics in depression, including studies registered on ClinicalTrials.gov (search: psilocybin, depression, Belgium). While the United States Food and Drug Administration (FDA) and United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) have both granted 'breakthrough therapy' or 'innovative medicine' designations for certain psychedelic compounds, no EU country has yet authorized routine clinical use outside trials.

This Belgian proposal is notable because it bridges the gap between research and practice, leveraging real-world evidence (RWE) to inform future regulatory decisions. Unlike expanded access or compassionate use programs, which are typically limited to life-threatening conditions, Belgium's model would create a pathway for broader, but still regulated, clinical deployment in psychiatry.

Policy and Research Implications for Europe

If implemented, Belgium’s policy could serve as a test case for other EU member states considering similar reforms. The move would likely accelerate the collection of RWE on psychedelic therapy safety, efficacy, and implementation logistics, providing valuable data to inform both national and European Medicines Agency (EMA) regulatory decisions. It could also catalyze updates to the EU Clinical Trials Regulation (Regulation (EU) No 536/2014) regarding post-trial access and innovative treatments.

For researchers, this development presents an opportunity to study outcomes in more diverse, real-world populations, potentially revealing both benefits and limitations not captured in tightly controlled trials. For clinicians, it raises questions about training standards, liability, and integration with existing mental health services. Notably, Belgium’s approach may require new reimbursement models, as most EU health systems do not currently cover psychedelic-assisted psychotherapy.

Risks, Oversight, and Unknowns

Allowing psychedelic therapy outside clinical trials introduces significant risks and unknowns, including safety concerns, potential for misuse, and the challenge of maintaining consistent treatment standards. The Belgian proposal reportedly includes robust oversight mechanisms: a national registry for all treated patients, mandatory adverse event reporting, and periodic policy review by an independent scientific committee. However, there is limited precedent for such programs in psychiatry, and real-world implementation may surface unanticipated issues—such as disparities in access or variable clinician adherence to protocols.

One failure mode not widely discussed in similar international proposals is the risk of "protocol drift," where clinicians gradually deviate from evidence-based protocols as real-world pressures mount. Belgium’s policy designers are reportedly considering random audits and ongoing clinician certification as safeguards, but the effectiveness of these measures remains to be seen.

Looking Forward: A European Precedent in the Making

Belgium’s potential move to permit psychedelic therapy for TRD outside clinical trials could reshape the European landscape for mental health innovation. If successful, it may prompt other EU states to pursue similar pathways, especially as demand for novel depression treatments grows. The next steps include public consultation, expert review, and possible pilot program launch in 2027. Stakeholders across research, clinical, and policy domains will be watching closely to assess both the benefits and the operational challenges of this pioneering approach.

By Dr. Elise Vandenberg, PhD (Neuropharmacology, KU Leuven). How we research: This article is based on direct review of Belgian regulatory announcements, clinical trial registries, and interviews with Belgian psychiatric policy advisors. Reviewed by Dr. Marc Delaere, MD, on 2026-10-18.